Spyre Therapeutics, Inc. (SYRE) income statement
SYRENasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 7/30
$93.47−4.16 (-4.26%)
Close on Nov 20, 2026Market cap $8.24BP/E –Yield –
Spyre Therapeutics, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, FY2025
- Gross margin
- –
- Operating margin
- –
- Net margin
- –
- Return on equity, FY2025
- -25.2%
Financial strength
- Current ratio
- 18.53
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 255.9%
Valuation
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 7.48
- Dividend yield
- –
See a number that looks wrong?